BMS | GenomeWeb

BMS

BMS has provided funding to the diagnostic company to support build-out of its new lab and development of its platform, which they hope can identify new biomarkers for Opdivo.

The partners aim to identify a microRNA-based signature that can predict lung cancer patient response to Bristol-Myers Squibb's immunotherapy Opdivo.

The companies will discover and develop microbiome-derived biomarkers, drug targets, and bioactive molecules for cancer.

The recent failure of Bristol-Myers Squibb's lung cancer immunotherapy to meet its primary endpoint demonstrates the challenge of working with imperfect biomarkers.

The company also said it has signed a collaboration deal with Bristol-Myers Squibb to evaluate the efficacy of immuno-oncology molecular profiling.

This type of test is intended to help guide personalized treatment, but will doctors order it and payors reimburse it if it's not required for the safe and effective use of a drug?

The test, when used as intended, allows doctors to gauge the magnitude of benefit melanoma patients might derive from the immunotherapeutic Opdivo.

Under the agreement, BMS has access to the 1,310 reagents in the public version of SomaLogic's SOMAscan assay along with a number of custom-developed reagents.

FDA has approved BMS' Opdivo with a test to guide treatment strategies, but according to the drug label testing isn't required to identify who should receive the drug.

In the study, called TAPUR, ASCO will give cancer patients who are out of treatment options off-label drugs based on their genomic data and record their outcomes in a registry.

Pages

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.